OptimizeRx Q4 revenue stable, beats estimates

OptimizeRx

05/03/2026 21:12

Overview

Healthcare tech firm's Q4 revenue stable at $32.2 mln, beating analyst expectations

Adjusted EBITDA for Q4 hit record $12 mln, exceeding analyst estimates

Company authorized $10 mln share repurchase program

Outlook

Company updates 2026 revenue guidance to $109-$114 mln

Company expects 2026 adjusted EBITDA between $21 mln and $25 mln

Result Drivers

GROSS PROFIT INCREASE - Q4 gross profit rose 9% year-over-year to $24.1 mln, indicating improved operational efficiency

RULE OF 40 ACHIEVEMENT - Co achieved Rule of 40 benchmark in 2025, reflecting balance of growth and profitability

Company press release: ID:nGNX2RN9FD

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$32.2 mln
$31.10 mln (6 Analysts)
Q4 Adjusted Net Income
Beat
$9.9 mln
$4.28 mln (5 Analysts)
Q4 Adjusted EBITDA
Beat
$12 mln
$5.72 mln (6 Analysts)
Q4 Gross Profit
$24.1 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the online services peer group is "buy"

Wall Street's median 12-month price target for OptimizeRx Corp is $24.00, about 205% above its March 4 closing price of $7.87

The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 18 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)